Abstract PO-123: Development of a 3D biomimetic metastatic liver niche model for pancreatic cancer

Author(s):  
Mahsa Pahlavan ◽  
Weikun Xiao ◽  
Flora Eun ◽  
Chang-Il Hwang ◽  
Reginald Hill
2021 ◽  
Author(s):  
Sheng Li ◽  
Moran Wang ◽  
Meiqi Liu

BACKGROUND Liver is a common metastatic organ for most malignancies, especially the pancreas. However, evidence for prognostic factors of pancreatic cancer metastasis to the liver at different ages is lacking. OBJECTIVE We aimed to evaluate the predictors of patients with pancreatic cancer metastasis to liver grouped by age of diagnosis. METHODS We chose the patients diagnosed between 2004 and 2015 from the SEER database. The primary lesions of metastatic liver cancer between sexes were compared using the Pearson’s chi-square test for categorical variables. The overall survival (OS) and cancer-specific survival (CSS) were the endpoint of the study. The prognostic factors were analyzed with the Kaplan-Meier method and log-rank test, and Cox proportional-hazards regression model. RESULTS The main primary sites of metastatic liver cancer for our patients are lung and brunchu, sigmoid colon, pancreas, which in males are lung and bronchu, sigmoid colon and pancreas, while breast, lung and bronchu, sigmoid colon in females. Furthermore, we explored the prognostic factors of pancreatic cancer metastasis to liver grouped by age at diagnosis. Tumor grade, histology and treatment are valid prognostic factors in all age groups. Additionally, gender and AJCC N stage in age<52 years old, while race and AJCC N stage in age>69 years old were predictors. Surgery alone was the optimal treatment in group age>69 years old, whereas surgery combined with chemotherapy was the best option in the other groups. CONCLUSIONS Our study evaluated the predictors of patients with pancreatic cancer metastasis to liver at various ages of diagnosis.


2021 ◽  
Vol 4 ◽  
Author(s):  
Meiqi Liu ◽  
Moran Wang ◽  
Sheng Li

Background: Liver is a common metastatic organ for most malignancies, especially the pancreas. However, evidence for prognostic factors of pancreatic cancer metastasis to the liver at different ages is lacking. Thus, we aimed to evaluate the predictors of patients with pancreatic cancer metastasis to liver grouped by age of diagnosis.Methods: We chose the patients diagnosed between 2004 and 2015 from the SEER database. The primary lesions of metastatic liver cancer between sexes were compared using the Pearson’s chi-square test for categorical variables. The overall survival (OS) and cancer-specific survival (CSS) were the endpoint of the study. The prognostic factors were analyzed with the Kaplan-Meier method and log-rank test, and Cox proportional-hazards regression model.Results: The main primary sites of metastatic liver cancer for our patients are lung and brunchu, sigmoid colon, pancreas, which in males are lung and bronchu, sigmoid colon and pancreas, while breast, lung and bronchu, sigmoid colon in females. Furthermore, we explored the prognostic factors of pancreatic cancer metastasis to liver grouped by age at diagnosis. Tumor grade, histology and treatment are valid prognostic factors in all age groups. Additionally, gender and AJCC N stage in age&lt;52 years old, while race and AJCC N stage in age &gt;69 years old were predictors. Surgery alone was the optimal treatment in group age&gt;69 years old, whereas surgery combined with chemotherapy was the best option in the other groups.Conclusion: Our study evaluated the predictors of patients with pancreatic cancer metastasis to liver at various ages of diagnosis.


Gut ◽  
2022 ◽  
pp. gutjnl-2021-325272
Author(s):  
Gaia Bellomo ◽  
Carolyn Rainer ◽  
Valeria Quaranta ◽  
Yuliana Astuti ◽  
Meirion Raymant ◽  
...  

ObjectivePancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease and cytotoxic chemotherapy is the standard of care treatment for patients with advanced disease. Here, we investigate how the microenvironment in PDAC liver metastases reacts to chemotherapy and its role in metastatic disease progression post-treatment, an area which is poorly understood.DesignThe impact of chemotherapy on metastatic disease progression and immune cell infiltrates was characterised using flow and mass cytometry combined with transcriptional and histopathological analysis in experimental PDAC liver metastases mouse models. Findings were validated in patient derived liver metastases and in an autochthonous PDAC mouse model. Human and murine primary cell cocultures and ex vivo patient-derived liver explants were deployed to gain mechanistical insights on whether and how chemotherapy affects the metastatic tumour microenvironment.ResultsWe show that in vivo, chemotherapy induces an initial infiltration of proinflammatory macrophages into the liver and activates cytotoxic T cells, leading only to a temporary restraining of metastatic disease progression. However, after stopping treatment, neutrophils are recruited to the metastatic liver via CXCL1 and 2 secretion by metastatic tumour cells. These neutrophils express growth arrest specific 6 (Gas6) which leads to AXL receptor activation on tumour cells enabling their regrowth. Disruption of neutrophil infiltration or inhibition of the Gas6/AXL signalling axis in combination with chemotherapy inhibits metastatic growth. Chemotherapy increases Gas6 expression in circulating neutrophils from patients with metastatic pancreatic cancer and recombinant Gas6 is sufficient to promote tumour cell proliferation ex vivo, in patient-derived metastatic liver explants.ConclusionCombining chemotherapy with Gas6/AXL or neutrophil targeted therapy could provide a therapeutic benefit for patients with metastatic pancreatic cancer.


2001 ◽  
Vol 120 (5) ◽  
pp. A162-A162
Author(s):  
A KUTUP ◽  
S HOSCH ◽  
S PAPE ◽  
P SCHEUNEMANN ◽  
W KNOEFEL ◽  
...  

2001 ◽  
Vol 120 (5) ◽  
pp. A610-A610
Author(s):  
D LEE ◽  
J LEE ◽  
S JEONG ◽  
K KWON ◽  
W CHOI ◽  
...  

2001 ◽  
Vol 120 (5) ◽  
pp. A261-A261
Author(s):  
T MASUI ◽  
S TUJI ◽  
J IDA ◽  
S NAKAJIMA ◽  
M KAWAGUCHI ◽  
...  
Keyword(s):  

2001 ◽  
Vol 120 (5) ◽  
pp. A336-A336
Author(s):  
M SHIMADA ◽  
A ANDOH ◽  
Y ARAKI ◽  
Y FUJIYAMA ◽  
T BAMBA

Sign in / Sign up

Export Citation Format

Share Document